Tirzepatide+b12
Those who have plateaued on semaglutide or want maximum fat loss results Tirzepatide targets both GLP-1 and GIP receptors simultaneously, producing stronger appetite suppression and greater fat loss than single agonist treatments. Combined with B12 for energy and tolerability support.
What is Tirzepatide + B12?
Tirzepatide is the first FDA-approved dual GIP and GLP-1 receptor agonist. This dual action provides superior weight loss results compared to single-action medications.
The addition of B12 supports metabolic function and helps prevent the fatigue that can accompany significant weight loss.
This combination represents the cutting edge of medical weight management, offering results that were previously difficult to achieve without surgical intervention.
What are the benefits?
Studies show tirzepatide can lead to weight loss of up to 22% of body weight, making it one of the most effective non-surgical weight loss treatments available.
Patients experience reduced appetite, improved blood sugar control, and often see improvements in cardiovascular risk factors.
The treatment is administered once weekly, making it convenient to incorporate into your lifestyle while our team monitors your progress remotely.


